Table 4 Basic values and variation ranges of model parameters
Parameter | Baseline value(¥) | Usage and dosage | Range(DSA) | Distribution(PSA) | Reference |
|---|---|---|---|---|---|
Sintilimab | 2160/200 mg | 200 mg/3 week | 5686–1512 | log-normal | MENET |
Carboplatin | 1.12/mg | 511.87 mg/3 week | ± 30% | log-normal | [6] |
Cisplatin | 1.35/mg | 130.5 mg/3 week | ± 30% | log-normal | [7] |
Pemetrexed | 2142/100 mg | 870 mg/3 week | ± 30% | log-normal | [6] |
Docetaxel | 1300/200 mg | 104.4 mg/3 week | ± 30% | log-normal | [8] |
Best supportive care | 2336 | ± 30% | log-normal | [6] | |
Drug management costs(sintilimab-combination group) | 56.25 | ± 30% | log-normal | [8] | |
Drug management costs(placebo-combination group) | 315.25 | ± 30% | log-normal | [6] | |
Disease management costs(sintilimab-combination group) | 372.42 | ± 30% | log-normal | [6] | |
Disease management costs(placebo-combination group) | 401.42 | ± 30% | log-normal | ||
Adverse event | |||||
Anemia | 1.17 | S: 15.0% P: 19.1% | [6] | ||
Decreased neutrophil count | 2877.4 | S: 36.5% P: 30.5% | [10] | ||
Decreased white blood count | 7845 | S: 14.7% P: 15.3% | [6] | ||
Decreased platelet | 23,086.04 | S: 12.0% P: 12.2% | [11] | ||
Cost of managing adverse event(sintilimab-combination group) | 4973.97 | ± 30% | |||
Cost of managing adverse event(placebo-combination group) | 4894.61 | ± 30% | |||
Effectiveness | |||||
PF state | 0.815 | 15% | Beta | [12] | |
PD state | 0.321 | 15% | Beta | [12] | |
Death state | 0 | ||||
Discount rate | 5% | 3%-8% | |||